Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors

Last revised by Daniel J Bell on 15 Apr 2024

Citation, DOI, disclosures and article data

Citation:

Weerakkody Y, Bell D, Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. Reference article, Radiopaedia.org (Accessed on 20 Apr 2024) https://doi.org/10.53347/rID-87567

DOI:

https://doi.org/10.53347/rID-87567

Permalink:

https://radiopaedia.org/articles/87567

rID:

87567

Article created:

8 Mar 2021, Yuranga Weerakkody ◉

Disclosures:

At the time the article was created Yuranga Weerakkody had no recorded disclosures.

View Yuranga Weerakkody's current disclosures

Last revised:

15 Apr 2024, Daniel J Bell ◉

Disclosures:

At the time the article was last revised Daniel J Bell had no financial relationships to ineligible companies to disclose.

View Daniel J Bell's current disclosures

Revisions:

2 times, by 2 contributors - see full revision history and disclosures

Systems:

Breast

Synonyms:

Cyclin-dependent kinase 4 and 6 inhibitors
CDK 4/6 inhibitors
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors
Cyclin-dependent kinase 4/6 inhibitors
Palbociclib
Abemaciclib
Ribociclib
Trilaciclib

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors including palbociclib, ribociclib, and abemaciclib are used in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer. Another CDK inhibitor, trilaciclib, has been found to reduce chemotherapy-induced myelosuppression in lung cancer.

Biology

CDK4 and CDK6 are downstream protein kinases in the estrogen signaling pathway which control entry into the cell cycle. This inhibition is thought to prevent tumor cell progression in the cell cycle.